Diagnosis and treatment of biliary malignancies: biopsy, cytology, cholangioscopy and stenting

Abstract

Biliary tract malignancies include cancers of the intra-hepatic and extra-hepatic bile ducts. Cholangiocarcinoma is the predominant biliary tract malignancy with nearly 60% of them occurring in the peri-hilar region. They can present with biliary strictures causing jaundice but can be insidious and present late in their clinical course. Recent advances in imaging and other diagnostic modalities help in the earlier identification of these tumors. Diagnosis should be suspected in anyone presenting with jaundice with evidence of biliary ductal dilatation or in patients with primary sclerosing cholangitis with worsening clinical status. The diagnostic approach consists of obtaining tumor markers, mainly CA 19-9, imaging modalities which include computed tomography and/or magnetic resonance imaging to establish the level of biliary obstruction and presence or absence of mass. Tissue sampling is performed with endoscopic retrograde cholangiopancreatography (ERCP) guided cytology and biopsies and with endoscopic ultrasound (EUS) if a mass is visible on imaging. Indeterminate strictures after initial biopsies could be further evaluated by cholangioscopy directed biopsies. Treatment for resectable and distal bile duct cancers involves surgical referral, but palliative biliary drainage is the key for unresectable cancers. Metal stents are generally preferred for distal cancers and plastic stents for proximal cancers. EUS guided biliary drainage can be an alternative approach in patients with failed ERCP.

Intraductal radiofrequency ablation plus biliary stent versus stent alone for malignant biliary obstruction: a systematic review and meta-analysis

“…The most common causes of MBO are cholangiocarcinoma (CCA) and pancreatic cancer (PC) [1]. The current management of MBO remains a significant challenge for diagnosis and treatment, as many patients present with unresectable disease, leading to increased morbidity and mortality [2]. For patients who are not surgical or transplant candidates, the bedrock of palliative treatment of MBO involves biliary drainage, accomplished through a combination of therapeutic endoscopy, radiotherapy, and/or chemotherapy.…”

“…2 = 2057.88; Chi 2 = 63.81, df = 2 (P <0.00001); I 2 = 97 % Test for overall eff ect: Z = 3.04 (P = 0.002) Forest plots: RFA + S vs S-aloneoverall survival in patients with CCA.de Oliveira Veras Matheus et al Intraductal radiofrequency ablation … Endosc Int Open 2024; 12: E23-E33 | © 2024. The Author(s).…”

“…2 = 0.00; Chi 2 = 6.96, df = 3 (P = 0.07); I 2 = 57 % Test for overall eff ect: Z = 1.16 (P = 0.21) 2 = 0.00; Chi 2 = 0.56, df = 3 (P = 0.91); I 2 = 0 % Test for overall eff ect: Z = 1.01 (P = 0.31) Fig.14Forest plots: RFA + S vs S-alonedetailed analysis of AEs.de Oliveira Veras Matheus et al Intraductal radiofrequency ablation … Endosc Int Open 2024; 12: E23-E33 | © 2024. The Author(s).…”

Endoscopic diagnosis and treatment for proximal biliary obstruction of tumor origin (literature review)

“…ЭРХПГ является признанным стандартом в диагностике билиарных стриктур. При этом генез можно предположить уже по данным холангиографии: протяженная асимметричная стриктура с неровными контурами наиболее вероятно является злокачественной [3]. Чувствительность и специфичность метода составляют 74 и 70% [2,4].…”